Artigos de revistas sobre o tema "Drug-reduced regimens"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Drug-reduced regimens".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
VanScoy, Brian, Jennifer McCauley, Sujata M. Bhavnani, Evelyn J. Ellis-Grosse e Paul G. Ambrose. "Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model". Antimicrobial Agents and Chemotherapy 60, n.º 9 (6 de junho de 2016): 5141–45. http://dx.doi.org/10.1128/aac.00355-16.
Texto completo da fonteAng, Zen Yang, Kit Yee Cheah, Nadiah B. Abdullah, Safawati B. Samsuri, Siao Hui Lee, Andrew WH Yem e Malathi AP Sriraman. "Parenteral cytotoxic drug wastage at a tertiary hospital in Kuala Lumpur: How much and why?" Journal of Oncology Pharmacy Practice 26, n.º 6 (6 de dezembro de 2019): 1306–17. http://dx.doi.org/10.1177/1078155219891209.
Texto completo da fonteVia, Laura E., Kathleen England, Danielle M. Weiner, Daniel Schimel, Matthew D. Zimmerman, Emmanuel Dayao, Ray Y. Chen et al. "A Sterilizing Tuberculosis Treatment Regimen Is Associated with Faster Clearance of Bacteria in Cavitary Lesions in Marmosets". Antimicrobial Agents and Chemotherapy 59, n.º 7 (4 de maio de 2015): 4181–89. http://dx.doi.org/10.1128/aac.00115-15.
Texto completo da fonteRhee, Soo-Yon, Philip M. Grant, Philip L. Tzou, Geoffrey Barrow, P. Richard Harrigan, John P. A. Ioannidis e Robert W. Shafer. "A systematic review of the genetic mechanisms of dolutegravir resistance". Journal of Antimicrobial Chemotherapy 74, n.º 11 (5 de julho de 2019): 3135–49. http://dx.doi.org/10.1093/jac/dkz256.
Texto completo da fonteTasneen, Rokeya, Fabrice Betoudji, Sandeep Tyagi, Si-Yang Li, Kathy Williams, Paul J. Converse, Véronique Dartois et al. "Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis". Antimicrobial Agents and Chemotherapy 60, n.º 1 (26 de outubro de 2015): 270–77. http://dx.doi.org/10.1128/aac.01691-15.
Texto completo da fonteHawkins, Trevor, Wenoah Veikley, Lucie Durand-Gasselin, Darius Babusis, Y. Sunila Reddy, John F. Flaherty e Adrian S. Ray. "Intracellular Nucleotide Levels during Coadministration of Tenofovir Disoproxil Fumarate and Didanosine in HIV-1-Infected Patients". Antimicrobial Agents and Chemotherapy 55, n.º 4 (31 de janeiro de 2011): 1549–55. http://dx.doi.org/10.1128/aac.00910-10.
Texto completo da fonteZhdanov, Konstantin V., Oleg V. Maltsev, Kristina V. Kasyanenko, Konstantin V. Kozlov, Vitalii S. Sukachev, Nikolai I. Lvov, Valerian V. Sharabkhanov e Alexander A. Litvinov. "Clinical efficiency and safety of riamilovir under various dosage regimens for treatment of acute respiratory viral infections in adults". Terapevticheskii arkhiv 95, n.º 11 (22 de dezembro de 2023): 930–36. http://dx.doi.org/10.26442/00403660.2023.11.202471.
Texto completo da fonteDutta, Noton K., Michael L. Pinn e Petros C. Karakousis. "Reduced Emergence of Isoniazid Resistance with Concurrent Use of Thioridazine against Acute Murine Tuberculosis". Antimicrobial Agents and Chemotherapy 58, n.º 7 (5 de maio de 2014): 4048–53. http://dx.doi.org/10.1128/aac.02981-14.
Texto completo da fonteJung, H., R. Medina, N. Castro, T. Corona e J. Sotelo. "Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen." Antimicrobial Agents and Chemotherapy 41, n.º 6 (junho de 1997): 1256–59. http://dx.doi.org/10.1128/aac.41.6.1256.
Texto completo da fonteTyczyńska, Agata, Marcela Krzysława Krzempek, Alexander Jorge Cortez, Artur Jurczyszyn, Katarzyna Godlewska, Hanna Ciepłuch, Edyta Subocz et al. "The Real-World Evidence on the Fragility and Its Impact on the Choice of Treatment Regimen in Newly Diagnosed Patients with Multiple Myeloma over 75 Years of Age". Cancers 15, n.º 13 (2 de julho de 2023): 3469. http://dx.doi.org/10.3390/cancers15133469.
Texto completo da fonteJung, Hyun Joo, e Nami McCarty. "Stem-Like Tumor Cells Confer Drug Resistant Properties to Mantle Cell Lymphoma". Blood 116, n.º 21 (19 de novembro de 2010): 1840. http://dx.doi.org/10.1182/blood.v116.21.1840.1840.
Texto completo da fonteCórdoba, J., N. M. Coronado-Álvarez, D. Parra e J. Parra-Ruiz. "In VitroActivities of Novel Antimicrobial Combinations against Extensively Drug-Resistant Acinetobacter baumannii". Antimicrobial Agents and Chemotherapy 59, n.º 12 (14 de setembro de 2015): 7316–19. http://dx.doi.org/10.1128/aac.00493-15.
Texto completo da fonteLubberman, Floor, Hans Gelderblom, Paul Hamberg, Walter Vervenne, Sasja F. Mulder, Frank Jansman, Angela Colbers et al. "A reduced pazopanib dose with food: Is it more patient-friendly and does it reduce drug costs?" Journal of Clinical Oncology 37, n.º 15_suppl (20 de maio de 2019): 4564. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.4564.
Texto completo da fonteShank, Kaitlyn R., Priya Koppikar, Neha Bhagwat, Matthew D. Keller, Franziska Michor, Ross L. Levine e Laura De Vargas Roditi. "Mathematical Optimization of JAK Inhibitor Dose and Scheduling for MPN Patients". Blood 124, n.º 21 (6 de dezembro de 2014): 911. http://dx.doi.org/10.1182/blood.v124.21.911.911.
Texto completo da fonteBhatti, Laveeza, e Jay Gladstein. "Once-Daily Nevirapine XR". Journal of the International Association of Physicians in AIDS Care 11, n.º 6 (27 de agosto de 2012): 369–73. http://dx.doi.org/10.1177/1545109712456427.
Texto completo da fonteRao, Gauri G., Neang S. Ly, Curtis E. Haas, Samira Garonzik, Alan Forrest, Jurgen B. Bulitta, Pamela A. Kelchlin et al. "New Dosing Strategies for an Old Antibiotic: Pharmacodynamics of Front-Loaded Regimens of Colistin at Simulated Pharmacokinetics in Patients with Kidney or Liver Disease". Antimicrobial Agents and Chemotherapy 58, n.º 3 (16 de dezembro de 2013): 1381–88. http://dx.doi.org/10.1128/aac.00327-13.
Texto completo da fonteHenegar, Cassidy, Emilio Letang, Ruolan Wang, Charles Hicks, Dainielle Fox, Bryn Jones, Annemiek de Ruiter e Vani Vannappagari. "A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings". Viruses 15, n.º 12 (14 de dezembro de 2023): 2426. http://dx.doi.org/10.3390/v15122426.
Texto completo da fonteSvensson, Elin M., Francesca Aweeka, Jeong-Gun Park, Florence Marzan, Kelly E. Dooley e Mats O. Karlsson. "Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis". Antimicrobial Agents and Chemotherapy 57, n.º 6 (9 de abril de 2013): 2780–87. http://dx.doi.org/10.1128/aac.00191-13.
Texto completo da fonteCraddock, Charles. "Pharmacological methods to reduce disease recurrence". Hematology 2013, n.º 1 (6 de dezembro de 2013): 63–69. http://dx.doi.org/10.1182/asheducation-2013.1.63.
Texto completo da fonteAziz, Muhammad Tahir. "Drug Interaction Exposures in an Intensive Care Unit: AntihypertensivePopulation". Journal of Applied Pharmacy 7 (2015): 41. http://dx.doi.org/10.21065/19204159.7.41.
Texto completo da fonteGonzalez-Juarrero, Mercedes, Lisa K. Woolhiser, Elizabeth Brooks, Mary Ann DeGroote e Anne J. Lenaerts. "Mouse Model for Efficacy Testing of Antituberculosis Agents via Intrapulmonary Delivery". Antimicrobial Agents and Chemotherapy 56, n.º 7 (30 de abril de 2012): 3957–59. http://dx.doi.org/10.1128/aac.00464-12.
Texto completo da fonteLu, Hong, e Sara Rosenbaum. "Developmental Pharmacokinetics in Pediatric Populations". Journal of Pediatric Pharmacology and Therapeutics 19, n.º 4 (1 de outubro de 2014): 262–76. http://dx.doi.org/10.5863/1551-6776-19.4.262.
Texto completo da fonteOvsyankina, E. S., L. V. Panova, E. A. Krushinskaya, O. A. Piskunova e F. G. Poluektova. "ON THE QUESTION OF REDUCED DURATION OF PULMONARY TB TREATMENT IN ADOLESCENTS WITH DRUG SUSCEPTIBILITY DETERMINATION DURING TREATMENT". Вестник ЦНИИТ 7, n.º 2 (2023): 67–72. http://dx.doi.org/10.57014/2587-6678-2023-7-2-67-72.
Texto completo da fonteTitov, K. S., E. V. Shutov, A. A. Alimov, S. S. Lebedev, A. A. Kirichek e G. M. Zapirov. "Nephrotoxicity of combination drug therapy in metastatic renal cancer". Cancer Urology 19, n.º 3 (16 de novembro de 2023): 153–62. http://dx.doi.org/10.17650/1726-9776-2023-19-3-153-162.
Texto completo da fonteHarris, Taylor N., e Lindsey R. Buscemi. "Evaluation of treatment simplification strategies in patients living with HIV with multi-drug resistance". Therapeutic Advances in Infectious Disease 10 (janeiro de 2023): 204993612211498. http://dx.doi.org/10.1177/20499361221149869.
Texto completo da fonteKukurika, А. V. "Economic aspects of using new chemotherapy regimens for multidrug and extensively drugresistant tuberculosis". FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 15, n.º 3 (9 de outubro de 2022): 353–62. http://dx.doi.org/10.17749/2070-4909/farmakoekonomika.2022.131.
Texto completo da fonteJames, Lyndon P., Fayette Klaassen, Sedona Sweeney, Jennifer Furin, Molly F. Franke, Reza Yaesoubi, Dumitru Chesov et al. "Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis". PLOS Medicine 21, n.º 5 (3 de maio de 2024): e1004401. http://dx.doi.org/10.1371/journal.pmed.1004401.
Texto completo da fonteBada, Florence O., Nick Blok, Evaezi Okpokoro, Saswata Dutt, Christopher Akolo, Patrick Dakum e Alash’le Abimiku. "Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria". PLOS ONE 15, n.º 12 (1 de dezembro de 2020): e0241065. http://dx.doi.org/10.1371/journal.pone.0241065.
Texto completo da fonteKelly, W. K., H. I. Scher, M. Mazumdar, D. Pfister, T. Curley, C. Leibertz, L. Cohen, V. Vlamis, A. Dnistrian e M. Schwartz. "Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer." Journal of Clinical Oncology 13, n.º 9 (setembro de 1995): 2214–22. http://dx.doi.org/10.1200/jco.1995.13.9.2214.
Texto completo da fonteBeelen, DW, K. Quabeck, U. Graeven, HG Sayer, HK Mahmoud e UW Schaefer. "Acute toxicity and first clinical results of intensive postinduction therapy using a modified busulfan and cyclophosphamide regimen with autologous bone marrow rescue in first remission of acute myeloid leukemia [see comments]". Blood 74, n.º 5 (1 de outubro de 1989): 1507–16. http://dx.doi.org/10.1182/blood.v74.5.1507.1507.
Texto completo da fonteBeelen, DW, K. Quabeck, U. Graeven, HG Sayer, HK Mahmoud e UW Schaefer. "Acute toxicity and first clinical results of intensive postinduction therapy using a modified busulfan and cyclophosphamide regimen with autologous bone marrow rescue in first remission of acute myeloid leukemia [see comments]". Blood 74, n.º 5 (1 de outubro de 1989): 1507–16. http://dx.doi.org/10.1182/blood.v74.5.1507.bloodjournal7451507.
Texto completo da fonteDing, Yajun, Robert Glaubius e Ume Abbas. "Drug Resistance After Failure of WHO Recommended First-Line Antiretroviral Regimen for Adult HIV-1 Infection in South Africa: A Modeling Analysis". Open Forum Infectious Diseases 4, suppl_1 (2017): S424. http://dx.doi.org/10.1093/ofid/ofx163.1067.
Texto completo da fonteTaft, David, Tarang Vora, Chen Ren, Patrick S. Zbyszewski, Joseph Morgan, Michael E. Petrone, Steven M. Fruchtman e Manoj Maniar. "Amelioration of Rigosertib Treatment Related Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes: Implementation of Novel Dosing Regimen Derived through Pharmacokinetic Modeling in Phase 2 Study of Oral Rigosertib in Combination with Azacitidine". Blood 132, Supplement 1 (29 de novembro de 2018): 4379. http://dx.doi.org/10.1182/blood-2018-99-118463.
Texto completo da fonteFekadu, Ginenus, Jiaqi Yao e Joyce H. S. You. "Bedaquiline-based treatment for extensively drug-resistant tuberculosis in South Africa: A cost-effectiveness analysis". PLOS ONE 17, n.º 8 (5 de agosto de 2022): e0272770. http://dx.doi.org/10.1371/journal.pone.0272770.
Texto completo da fonteLiu, Ying, Samyukta Mullangi, Xiaoxue Chen, Timothy Pham, David Joseph Debono, Michael Jordan Fisch, Aliza Gordon e Dawn L. Hershman. "Association between oncology clinical pathway utilization and quality and cost outcomes in patients with metastatic solid tumors." Journal of Clinical Oncology 40, n.º 28_suppl (1 de outubro de 2022): 430. http://dx.doi.org/10.1200/jco.2022.40.28_suppl.430.
Texto completo da fonteShang, Shaobin, Crystal A. Shanley, Megan L. Caraway, Eileen A. Orme, Marcela Henao-Tamayo, Laurel Hascall-Dove, David Ackart et al. "Activities of TMC207, Rifampin, and Pyrazinamide againstMycobacterium tuberculosisInfection in Guinea Pigs". Antimicrobial Agents and Chemotherapy 55, n.º 1 (11 de outubro de 2010): 124–31. http://dx.doi.org/10.1128/aac.00978-10.
Texto completo da fonteKaufmann, Gilbert R., Nina Khanna, Rainer Weber, Luc Perrin, Hansjakob Furrer, Matthias Cavassini, Bruno Ledergerber et al. "Long-Term Virological Response to Multiple Sequential Regimens of Highly Active Antiretroviral Therapy for HIV Infection". Antiviral Therapy 9, n.º 2 (fevereiro de 2004): 263–74. http://dx.doi.org/10.1177/135965350400900212.
Texto completo da fonteVaughan, William P., Amy G. Nance e Donna E. Salzman. "Improving Dosing Precision in Buslfan (BU) Based Preparative Regimens for Hematopoietic Stem Cell Transplantation (HSCT)." Blood 104, n.º 11 (16 de novembro de 2004): 1148. http://dx.doi.org/10.1182/blood.v104.11.1148.1148.
Texto completo da fonteGray, Adam Thorburn, Liana Macpherson, Ffion Carlin, Bianca Sossen, Alexandra S. Richards, Sandra V. Kik, Rein M. G. J. Houben et al. "Treatment for radiographically active, sputum culture-negative pulmonary tuberculosis: A systematic review and meta-analysis". PLOS ONE 18, n.º 11 (16 de novembro de 2023): e0293535. http://dx.doi.org/10.1371/journal.pone.0293535.
Texto completo da fonteSoeny, Kabir, Barbara Bogacka e Byron Jones. "Dose optimisation with simultaneous pharmacokinetic estimation in adaptive clinical trials". Statistical Methods in Medical Research 29, n.º 4 (7 de junho de 2019): 1149–66. http://dx.doi.org/10.1177/0962280219852582.
Texto completo da fonteNsengiyumva, Ntwali Placide, Jonathon R. Campbell, Olivia Oxlade, Juan F. Vesga, Christian Lienhardt, Anete Trajman, Dennis Falzon, Saskia Den Boon, Nimalan Arinaminpathy e Kevin Schwartzman. "Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness". PLOS Medicine 19, n.º 6 (13 de junho de 2022): e1004032. http://dx.doi.org/10.1371/journal.pmed.1004032.
Texto completo da fonteMcCruden, D. C., T. E. Hilditch, J. M. C. Connell e W. D. Alexander. "Kinetics of [123I]iodide uptake and discharge by perchlorate in studies of inhibition of iodide binding by antithyroid drugs". Acta Endocrinologica 110, n.º 4 (dezembro de 1985): 499–504. http://dx.doi.org/10.1530/acta.0.1100499.
Texto completo da fonteChalchal, Hafsah, Vinita Dhir, Kalina Abrol, Michelle Boyce, Michelle Delbaere, Ashish Masurekar, Mike Kennah et al. "Favorable Outcomes with Low Dose Anti Thymocyte Globulin Based Graft Versus Host Disease Prophylaxis after Mismatched Unrelated Donor Allogenic Hematopoietic Cell Transplantation". Blood 142, Supplement 1 (28 de novembro de 2023): 7002. http://dx.doi.org/10.1182/blood-2023-182274.
Texto completo da fonteSiddiqui, Abdul Aziz, Kazi Najamus-saqib Khan, Arafat Ali Farooqui, Muhammad Saad Farooqi, Muhammad Junaid Tariq e Faiz Anwer. "Three Drug Regimens for Newly Diagnosed Multiple Myeloma Transplant-Ineligible Elderly Patients - a Systematic Review". Blood 134, Supplement_1 (13 de novembro de 2019): 5574. http://dx.doi.org/10.1182/blood-2019-132095.
Texto completo da fonteWinters, Mark A., e Thomas C. Merigan. "Variants Other than Aspartic Acid at Codon 69 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene Affect Susceptibility to Nucleoside Analogs". Antimicrobial Agents and Chemotherapy 45, n.º 8 (1 de agosto de 2001): 2276–79. http://dx.doi.org/10.1128/aac.45.8.2276-2279.2001.
Texto completo da fonteHan, Win Min, Wiriya Mahikul, Thomas Pouplin, Saranath Lawpoolsri, Lisa J. White e Wirichada Pan-Ngum. "Assessing the impacts of short-course multidrug-resistant tuberculosis treatment in the Southeast Asia Region using a mathematical modeling approach". PLOS ONE 16, n.º 3 (26 de março de 2021): e0248846. http://dx.doi.org/10.1371/journal.pone.0248846.
Texto completo da fonteRolsma, Stephanie L., Andrew G. Sokolow, Guohua An, Nick Fishbane, William Fissell, Kenan Gu, Natalia Jimenez et al. "Are We Dosing Correctly? Population Pharmacokinetic Modeling of Cefepime, Piperacillin-Tazobactam, and Meropenem in Individuals with Cystic Fibrosis". Journal of the Pediatric Infectious Diseases Society 12, Supplement_1 (1 de novembro de 2023): S8. http://dx.doi.org/10.1093/jpids/piad070.015.
Texto completo da fonteStone, Chris, Mounir Ait-Khaled, Charles Craig, Philip Griffin e Margaret Tisdale. "Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutation Selection during In Vitro Exposure to Tenofovir Alone or Combined with Abacavir or Lamivudine". Antimicrobial Agents and Chemotherapy 48, n.º 4 (abril de 2004): 1413–15. http://dx.doi.org/10.1128/aac.48.4.1413-1415.2004.
Texto completo da fonteFedorin, Andrey Aleksandrovich, Nikolay Alexandrovich Pudovkin, Yulia Rifovna Borodina e Sergey Dmitrievich Klyukin. "Comparative effectiveness of flea allergic dermatitis treatment regimens in dogs and cats". Agrarian Scientific Journal, n.º 8 (10 de setembro de 2021): 78–81. http://dx.doi.org/10.28983/asj.y2021i8pp78-81.
Texto completo da fonteYu, Zaikuan J., Eric P. Mosher e Namandjé N. Bumpus. "Pharmacogenomics of Antiretroviral Drug Metabolism and Transport". Annual Review of Pharmacology and Toxicology 61, n.º 1 (6 de janeiro de 2021): 565–85. http://dx.doi.org/10.1146/annurev-pharmtox-021320-111248.
Texto completo da fonte